MICHIELS, Jan Jacques, Petr SMEJKAL, Miroslav PENKA, Angelika BATOROVA, Tatiana PRICANGOVA, Ulrich BUDDE, Inge VANGENECHTEN and Alain GADISSEUR. Diagnostic Differentiation of von Willebrand Disease Types 1 and 2 by von Willebrand Factor Multimer Analysis and DDAVP Challenge Test. Clinical and Applied Thrombosis-Hemostasis. Thousand Oaks: Sage Publications Inc., 2017, vol. 23, No 6, p. 518-531. ISSN 1076-0296. Available from: https://dx.doi.org/10.1177/1076029616647157.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Diagnostic Differentiation of von Willebrand Disease Types 1 and 2 by von Willebrand Factor Multimer Analysis and DDAVP Challenge Test
Authors MICHIELS, Jan Jacques (528 Netherlands), Petr SMEJKAL (203 Czech Republic, guarantor, belonging to the institution), Miroslav PENKA (203 Czech Republic, belonging to the institution), Angelika BATOROVA (703 Slovakia), Tatiana PRICANGOVA (703 Slovakia), Ulrich BUDDE (276 Germany), Inge VANGENECHTEN (56 Belgium) and Alain GADISSEUR (56 Belgium).
Edition Clinical and Applied Thrombosis-Hemostasis, Thousand Oaks, Sage Publications Inc. 2017, 1076-0296.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30205 Hematology
Country of publisher United States of America
Confidentiality degree is not subject to a state or trade secret
Impact factor Impact factor: 1.852
RIV identification code RIV/00216224:14110/17:00095968
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1177/1076029616647157
UT WoS 000407813600003
Keywords in English von Willebrand disease; von Willebrand factor; ADAMTS13; DDAVP; von Willebrand factor assays; von Willebrand factor multimers; von Willebrand factor mutations
Tags EL OK
Tags International impact, Reviewed
Changed by Changed by: Soňa Böhmová, učo 232884. Changed: 20/3/2018 11:43.
Abstract
The European Clinical Laboratory and Molecular (ECLM) classification of von Willebrand disease (vWD) is based on the splitting approach which uses sensitive and specific von Willebrand factor (vWF) assays with regard to the updated molecular data on structure and function of vWF gene and protein defects. A complete set of FVIII:C and vWF ristocetine cofactor, collagen binding, and antigen, vWF multimeric analysis in low- and medium-resolution gels, and responses to desmopressin (DDAVP) of FVIII:C and vWF parameters are mandatory. The ECLM classification distinguishes recessive types 1 and 3 vWD from recessive vWD 2C due to mutations in the D1 and D2 domains and vWD 2N due to mutations in the D-FVIII-binding domain of vWF. The ECLM classification differentiates between mild vWD type 1 with variable penetrance of bleedings from symptomatic dominant type 1 vWD secretion defect and/or clearance defect with normal vWF multimers versus vWD 1M and 2M with normal or smeary vWF multimers in low- and medium-resolution gels. High-quality multimeric analysis of vWF in medium-resolution gels based on a DDAVP challenge test clearly delineates and distinguishes each of the dominant type 2 vWDs 1/2E, 2M, 2B, 2A, and 2D caused by vWF gene mutations in the D3 multimerization domain, loss or gain-of-function mutations in the glycoprotein Ib receptor A1 domain, gene mutations in the A2 proteolytic domain, and the C-terminal dimerization domain, respectively.
PrintDisplayed: 24/4/2024 19:45